Kalaris Therapeutics, Inc. Common Stock KLRS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$43.44M+37.2% | -$69.17M+63.7% | -$190.42M— | —— | ||
| —— | —— | $398K— | —— | ||
| $1.94M+116% | $895K-97.8% | $40.78M— | —— | ||
| -$38.37M-85.6% | -$20.67M+83.4% | -$124.45M— | —— | ||
| -$19.72M-121% | $95M— | —— | —— | ||
| —— | $19.14M— | —— | $126.96M+54,625% | ||
| —— | -$1.53M+90.4% | -$15.97M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kalaris Therapeutics, Inc. Common Stock generate?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?
- After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.
- Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.